Reading, US
Christopher Reading, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20080221074 | Drug Screen and Treatment Method - The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4α-fluoro-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3β,7α,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3α,7β,17β-triol and 4α-fluoro-17α-ethynylandrost-5-ene-3β,17β-triol-7-one. | 09-11-2008 |
Christopher L. Reading, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20090143349 | STEROID TETROL SOLID STATE FORMS - The invention relates to solid state forms of androst-5-ene-3β,7β,16α,17β-triol, formulations containing or prepared from such solid state forms and use of such materials for modulating acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity such as arthritis, multiple sclerosis, ulcerative colitis or Type 1 diabetes. The formulations can also be used to prevent, treat or slow the progression of conditions related to metabolic disorders such as Type 2 diabetes. | 06-04-2009 |
20090215737 | Pharmaceutical Compositions - 2 - The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations. | 08-27-2009 |
20100075937 | Patient populations and treatment methods - The invention provides, inter alia, methods to treat, e.g., hyperglycemia or diabetes patients having two or more of a BMI of at least 28 or 29, a fasting insulin level of at least 4 μU/mL or at least 6 μU/mL and optionally (i) a serum MCP1 level of at least about 400 pg/mL or at least about 500 pg/mL. The treatment method includes administering 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol and optionally another compound such as metformin or glyburide. Specific embodiments include use of 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol for the treatment of hypercholesterolemia in a patient and a BMI of at least 28 or 29 and optionally hyperglycemia. In these embodiments, the patient will most preferably have a fasting insulin level of at least 4 μU/mL or at least 5 μU/mL. | 03-25-2010 |
20100222315 | Patient populations and treatment methods - The invention provides 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol for use in methods to treat, e.g., hyperglycemia or diabetes patients having a body mass index of at least about 31 (≧30.5, ≧31 or ≧32), wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will generally have a fasting insulin level of at least 4 μU/mL or another characteristic as described herein. | 09-02-2010 |
20100227841 | Patient populations and treatment methods - The invention provides 17α-ethynylandrost-5-ene-3β,7β,17β-triol for use in methods to treat, e.g., pre-diabetic hyperglycemia or type 2 diabetes patients having a fasting blood glucose level of at least 110 mg/dL or a post prandial glucose level of at least about 140 mg/dL an optionally a body mass index of >29.9, wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will preferably have a fasting insulin level of at least 3.5 to 4 μU/mL. | 09-09-2010 |
20140010806 | Treatment of Ocular Diseases - The invention relates to methods to use 17α-ethynylandrost-5-ene-3β,7β,17β-triol to treat ocular diseases or conditions such as dry eye, uveitis or retinitis. The compound can be administered topically to the eye, by intravitreal injection or systemically, e.g., orally. | 01-09-2014 |
Eamonn Reading US
Patent application number | Description | Published |
---|---|---|
20150346214 | DETECTION OF MEMBRANE PROTEINS - According to the present invention, there is provided a method of detecting a membrane protein by mass spectrometry, the method comprising the steps of: (a) providing a solution comprising a detergent micelle in which said membrane protein is contained, wherein said solution contains a polyoxyalkylene glycol detergent; (b) providing a mass spectrometer comprising a nanoelectrospray ionisation source, a mass analyser and a detector; (c) vaporising the solution using the nanoelectrospray ionisation source under conditions such that the membrane protein is released from the micelle; (d) ionising the membrane protein; (e) resolving the ionised membrane protein using the mass analyser; and (f) detecting the resolved membrane protein using the detector. Also provided are reagents for use in said method. | 12-03-2015 |
Julian Reading, Frederick, MD US
Patent application number | Description | Published |
---|---|---|
20140088006 | Stem Cell Mobilization and Tissue Repair and Regeneration - Stem cells are mobilized from bone marrow by administering an amount of Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gin-Val (SEQ ID NO: 1) effective to mobilize the stem cells. This method is useful for promoting preservation, repair, or regeneration of bodily tissue, or revascularization, in a patient in need of such treatment. Alternatively, the mobilized stem cells can be collected for transplant. | 03-27-2014 |
Leslie J. Reading, Lakeside, CA US
Patent application number | Description | Published |
---|---|---|
20130109375 | WIRELESS TRACKING OF POWER TOOLS AND RELATED DEVICES | 05-02-2013 |
20140006295 | DIGITAL CHAIN-OF-CUSTODY | 01-02-2014 |
20140240125 | WIRELESS TRACKING OF POWER TOOLS AND RELATED DEVICES - A power distribution box includes a power input configured to receive power from an external power source, an alternating current (AC) output electrically coupled to the power input, a power-line adapter and a gateway device. The power-line adapter is coupled to the power input and configured to receive power via the power input and communicate with an external network. The gateway device is coupled to the power-line adapter and is configured to communicate with the external network. The gateway device includes a wireless network module configured to communicate with at least one power tool device in a wireless network, and a translation controller configured to enable communications between the wireless network module and the external network through the power-line adapter. | 08-28-2014 |
Mike Reading US
Patent application number | Description | Published |
---|---|---|
20080283755 | High frequency deflection measurement of IR absorption - An AFM based technique has been demonstrated for performing highly localized IR spectroscopy on a sample surface. Such a technique implemented in a commercially viable analytical instrument would be extremely useful. Various aspects of the experimental set-up have to be changed to create a commercial version. The invention addresses many of these issues thereby producing a version of the analytical technique that cab be made generally available to the scientific community. | 11-20-2008 |
20090249521 | High frequency deflection measurement of IR absorption - An AFM based technique has been demonstrated for performing highly localized IR spectroscopy on a sample surface. Such a technique implemented in a commercially viable analytical instrument would be extremely useful. Various aspects of the experimental set-up have to be changed to create a commercial version. The invention addresses many of these issues thereby producing a version of the analytical technique that cab be made generally available to the scientific community. | 10-01-2009 |